Update in systemic sclerosis-associated pulmonary arterial hypertension

Mohamed A. Gashouta, Marc Humbert, Paul M Hassoun

Research output: Contribution to journalArticle

Abstract

Pulmonary arterial hypertension (PAH) is one of the leading causes of death in systemic sclerosis (SSc). Despite advances in treatment options for PAH, long-term prognosis remains poor for scleroderma-associated PAH (SSc-PAH). Although prompt diagnosis and treatment of PAH may have significant impact on survival rates, early detection of the syndrome continues to be challenging in SSc due to several factors ranging from limitations of the current screening tools and the complexities of the disease. In comparison with other PAH subgroups, SSc-PAH patients respond poorly to conventional forms of PAH therapy. Recent findings indicate that factors such as autoimmune and inflammatory responses, more severe vasculature remodeling, and intrinsic cardiac involvement may account for these differences.

Original languageEnglish (US)
Pages (from-to)293-304
Number of pages12
JournalPresse Medicale
Volume43
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Systemic Scleroderma
Pulmonary Hypertension
Autoimmunity
Cause of Death
Therapeutics
Survival Rate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Update in systemic sclerosis-associated pulmonary arterial hypertension. / Gashouta, Mohamed A.; Humbert, Marc; Hassoun, Paul M.

In: Presse Medicale, Vol. 43, No. 10, 01.10.2014, p. 293-304.

Research output: Contribution to journalArticle

Gashouta, Mohamed A. ; Humbert, Marc ; Hassoun, Paul M. / Update in systemic sclerosis-associated pulmonary arterial hypertension. In: Presse Medicale. 2014 ; Vol. 43, No. 10. pp. 293-304.
@article{f667af97eb814f20bbd319904eff0321,
title = "Update in systemic sclerosis-associated pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension (PAH) is one of the leading causes of death in systemic sclerosis (SSc). Despite advances in treatment options for PAH, long-term prognosis remains poor for scleroderma-associated PAH (SSc-PAH). Although prompt diagnosis and treatment of PAH may have significant impact on survival rates, early detection of the syndrome continues to be challenging in SSc due to several factors ranging from limitations of the current screening tools and the complexities of the disease. In comparison with other PAH subgroups, SSc-PAH patients respond poorly to conventional forms of PAH therapy. Recent findings indicate that factors such as autoimmune and inflammatory responses, more severe vasculature remodeling, and intrinsic cardiac involvement may account for these differences.",
author = "Gashouta, {Mohamed A.} and Marc Humbert and Hassoun, {Paul M}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.lpm.2014.06.007",
language = "English (US)",
volume = "43",
pages = "293--304",
journal = "Presse Medicale",
issn = "0755-4982",
publisher = "Elsevier Masson",
number = "10",

}

TY - JOUR

T1 - Update in systemic sclerosis-associated pulmonary arterial hypertension

AU - Gashouta, Mohamed A.

AU - Humbert, Marc

AU - Hassoun, Paul M

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Pulmonary arterial hypertension (PAH) is one of the leading causes of death in systemic sclerosis (SSc). Despite advances in treatment options for PAH, long-term prognosis remains poor for scleroderma-associated PAH (SSc-PAH). Although prompt diagnosis and treatment of PAH may have significant impact on survival rates, early detection of the syndrome continues to be challenging in SSc due to several factors ranging from limitations of the current screening tools and the complexities of the disease. In comparison with other PAH subgroups, SSc-PAH patients respond poorly to conventional forms of PAH therapy. Recent findings indicate that factors such as autoimmune and inflammatory responses, more severe vasculature remodeling, and intrinsic cardiac involvement may account for these differences.

AB - Pulmonary arterial hypertension (PAH) is one of the leading causes of death in systemic sclerosis (SSc). Despite advances in treatment options for PAH, long-term prognosis remains poor for scleroderma-associated PAH (SSc-PAH). Although prompt diagnosis and treatment of PAH may have significant impact on survival rates, early detection of the syndrome continues to be challenging in SSc due to several factors ranging from limitations of the current screening tools and the complexities of the disease. In comparison with other PAH subgroups, SSc-PAH patients respond poorly to conventional forms of PAH therapy. Recent findings indicate that factors such as autoimmune and inflammatory responses, more severe vasculature remodeling, and intrinsic cardiac involvement may account for these differences.

UR - http://www.scopus.com/inward/record.url?scp=84908401106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908401106&partnerID=8YFLogxK

U2 - 10.1016/j.lpm.2014.06.007

DO - 10.1016/j.lpm.2014.06.007

M3 - Article

C2 - 25179278

AN - SCOPUS:84908401106

VL - 43

SP - 293

EP - 304

JO - Presse Medicale

JF - Presse Medicale

SN - 0755-4982

IS - 10

ER -